Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 29, 2025, Thomas Sweeney notified the board of directors (the “Board”) of Oaktree Acquisition Corp. III Life Sciences (the “Company”) of his resignation as Chief Financial Officer of the Company. The resignation was effective on October 29, 2025. Mr. Sweeney’s resignation was not the result of any disagreements with the Board or management of the Company and he is resigning to pursue other professional opportunities. On October 29, 2025, the Board appointed George A. Martinez as the new Chief Financial Officer (principal accounting and principal financial officer) of the Company, effective immediately. Mr. Martinez is a Senior Vice President with Oaktree Capital Management, L.P.’s (with its affiliates, as applicable, “Oaktree”) finance organization, overseeing various accounting, operations and reporting functions for Oaktree’s corporate accounting organization. Prior to joining Oaktree in 2024, Mr. Martinez was an Audit Senior Manager at Ernst & Young, serving clients in the real estate and financial services industries from 2013 to 2024. Mr. Martinez is a Certified Public Accountant in the state of California and a member of the American Institute of Certified Public Accountants. He received a Master of Accounting from the University of Southern California, and a Bachelor of Arts from Occidental College, where he was a politics major. Mr. Martinez will not be compensated by the Company for his services as Chief Financial Officer of the Company and he has not entered into an employment agreement with the Company. In connection with his appointment, Mr. Martinez is expected to enter into an Indemnity Agreement and a Letter Agreement with the Company on the same terms as the other directors and officers of the Company that executed similar agreements at the time of the consummation of the Company’s initial public offering. The Indemnity Agreement and Letter Agreement will be in the form of the agreements that are filed as exhibits to the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission on March 27, 2025. Other than the foregoing, Mr. Martinez is not party to any arrangement or understanding with any person pursuant to which he was appointed as an executive officer of the Company, nor is he party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. There are no family relationships between Mr. Martinez and any of the Company’s directors and executive officers. 2
OACC Oaktree Acquisition Corp. III Life Sciences - 8-K
Accession
0001193125-25-2566045.02
Item 5.02 - Departure/Election of Directors or Certain Officers
415 words